Table 3.
Representative lipid-based miRNA delivery systems for regenerative medicine
| Transfection reagents | Target miRNA | Cell type | Therapeutic approaches | MiRNA level variation | Potential application | Ref. |
|---|---|---|---|---|---|---|
| HiPerFect | MiR-146b-5 p; miR-23b; miR-99a | Human neural stem cells | Replacement | MiR-146b-5p: ~65 fold increase; miR-23b: 30 fold increase; miR-99a: 25 fold increase | Neurogenesis | [149] |
| DharmaFECT® | MiR-198 | keratinocytes | Replacement | >3 fold increase | Promoting wound healing | [63] |
| SiPORT™ NeoFX™ | MiR-21 | MSCs | Replacement | ~600 fold increase | Osteogenesis | [150] |
| SiPORT™ NeoFX™ | MiR-335-5p | Primary calvarial osteoblasts | Replacement | Transfection efficiency ~40% | Osteogenesis | [151] |
| SiPORT™ NeoFX™ | MiR-17 | human periodontal ligament tissue-derived mesenchymal stem cells | Replacement | >4000 fold increase | Osteogenesis | [152] |
| SiPORT™ NeoFX™ | MiR-1; miR-499 | human cardiomyocyte progenitor cells | Replacement | miR-1: increase to 8 ΔΔ Ct; miR-499: increase to 12 ΔΔCt | Cardiomyogenesis | [153] |
| Lipofectamine® 2000 | MiR-1 | ESC | Inhibition | ~90% down regulation of ESC differentiation | Osteogenesis | [154] |
| Lipofectamine® 2000 | MiR-375 | 3T3-L1 adipocyte | Inhibition | ~80% knockdown | Adipogenesis | [155] |
| Lipofectamine® RNAi-MAX | MiR-720 | hDPCs | Replacement | ~180 fold increase | Osteogenesis | [148] |
| Lipofectamine® RNAiMAX | MiR-682 | Myogenic progenitor cell | Inhibition | ~50% knockdown | Myogenesis | [156] |